In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $6.00. The company’s shares closed last Thursday at $1.51.
According to TipRanks, Selvaraju is an analyst with an average return of -28.2% and a 22.22% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Enlivex, Rockwell Med, and Oramed Pharm.
Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $6.00.
See the top stocks recommended by analysts >>
Based on Spero Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $51.28 million and a net profit of $26.77 million. In comparison, last year the company earned a revenue of $15.44 million and had a GAAP net loss of $29.24 million
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SPRO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
Read More on SPRO:
- Biotech Alert: Searches spiking for these stocks today
- Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Spero Therapeutics reports Q4 EPS 55c, consensus 4c
- Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
- Spero Therapeutics (SPRO) Q4 Earnings Cheat Sheet
